Regulation of homeostasis and oncogenesis in the intestinal epithelium by Ras

Experimental Cell Research

Volumn 317, Issue 19, 2011, Pages 2732-2739

  Velho, Sergia ^a,b,c   Haigis, Kevin M ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF PORTO   (Portugal)

Author keywords

Colorectal cancer; Intestinal epithelium; K ras

Indexed keywords

APC PROTEIN; ARF PROTEIN; BETA CATENIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; K RAS PROTEIN; ONCOPROTEIN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2;

ANGIOGENESIS; CANCER CELL CULTURE; CANCER GENETICS; CANCER GROWTH; CARCINOGENESIS; CELL PROLIFERATION; COLORECTAL CANCER; DELETION MUTANT; GENE MUTATION; GENE TARGETING; GENETIC ENGINEERING; HOMEOSTASIS AND REGULATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INTESTINE CRYPT; INTESTINE EPITHELIUM; MOLECULAR GENETICS; NONHUMAN; ONCOGENE; PHENOTYPE; POINT MUTATION; PRIORITY JOURNAL; REVIEW;

EID: 80455174751     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2011.06.002     Document Type: Review

References (61)

1. Lau K.S., Haigis K.M. Non-redundancy within the RAS oncogene family: insights into mutational disparities in cancer. Mol. Cells 2009, 28:315-320.
2. Hancock J.F. Ras proteins: different signals from different locations. Nat. Rev. Mol. Cell. Biol. 2003, 4:373-384.
3. Malumbres M., Barbacid M. RAS oncogenes: the first 30 years. Nat. Rev. Cancer 2003, 3:459-465.
4. Yeh J.J., Madigan J.P., Campbell P.M., Roberts P.J., DeGraffenreid L., Der C.J. Targeting Ras for anticancer drug discovery. Handbook of Cell Signaling 2009, Vol. 3:2837-2857. Academic Press, Oxford. 2nd ed. R.A. Bradshaw, E.A. Dennis (Eds.).
5. Bos J.L., Fearon E.R., Hamilton S.R., Verlaan-de Vries M., van Boom J.H., van der Eb A.J., Vogelstein B. Prevalence of ras gene mutations in human colorectal cancers. Nature 1987, 327:293-297.
6. Vogelstein B., Fearon E.R., Hamilton S.R., Kern S.E., Preisinger A.C., Leppert M., Nakamura Y., White R., Smits A.M., Bos J.L. Genetic alterations during colorectal-tumor development. New Engl. J. Med. 1988, 319:525-532.
7. Irahara N., Baba Y., Nosho K., Shima K., Yan L., Dias-Santagata D., Iafrate A.J., Fuchs C.S., Haigis K.M., Ogino S. NRAS mutations are rare in colorectal cancer. Diagn. Mol. Pathol. 2010, 19:157-163.
8. Janakiraman M., Vakiani E., Zeng Z., Pratilas C.A., Taylor B.S., Chitale D., Halilovic E., Wilson M., Huberman K., Ricarte Filho J.C., Persaud Y., Levine D.A., Fagin J.A., Jhanwar S.C., Mariadason J.M., Lash A., Ladanyi M., Saltz L.B., Heguy A., Paty P.B., Solit D.B. Genomic and biological characterization of exon 4 KRAS mutations in human cancer. Cancer Res. 2010, 70:5901-5911.
9. Edkins S., O'Meara S., Parker A., Stevens C., Reis M., Jones S., Greenman C., Davies H., Dalgliesh G., Forbes S., Hunter C., Smith R., Stephens P., Goldstraw P., Nicholson A., Chan T.L., Velculescu V.E., Yuen S.T., Leung S.Y., Stratton M.R., Futreal P.A. Recurrent KRAS codon 146 mutations in human colorectal cancer. Cancer Biol. Ther. 2006, 5:928-932.
10. O'Brien M.J. Hyperplastic and serrated polyps of the colorectum. Gastroenterol Clin. North Am. 2007, 36:947-968. viii.
11. Velho S., Moutinho C., Cirnes L., Albuquerque C., Hamelin R., Schmitt F., Carneiro F., Oliveira C., Seruca R. BRAF, KRAS and PIK3CA mutations in colorectal serrated polyps and cancer: primary or secondary genetic events in colorectal carcinogenesis?. BMC Cancer 2008, 8:255.
12. Ohnishi T., Tomita N., Monden T., Ohue M., Yana I., Takami K., Yamamoto H., Yagyu T., Kikkawa N., Shimano T., Monden M. A detailed analysis of the role of K-ras gene mutation in the progression of colorectal adenoma. Brit. J. Cancer 1997, 75:341-347.
13. Andreyev H.J., Norman A.R., Cunningham D., Oates J., Dix B.R., Iacopetta B.J., Young J., Walsh T., Ward R., Hawkins N., Beranek M., Jandik P., Benamouzig R., Jullian E., Laurent-Puig P., Olschwang S., Muller O., Hoffmann I., Rabes H.M., Zietz C., Troungos C., Valavanis C., Yuen S.T., Ho J.W., Croke C.T., O'Donoghue D.P., Giaretti W., Rapallo A., Russo A., Bazan V., Tanaka M., Omura K., Azuma T., Ohkusa T., Fujimori T., Ono Y., Pauly M., Faber C., Glaesener R., de Goeij A.F., Arends J.W., Andersen S.N., Lovig T., Breivik J., Gaudernack G., Clausen O.P., De Angelis P.D., Meling G.I., Rognum T.O., Smith R., Goh H.S., Font A., Rosell R., Sun X.F., Zhang H., Benhattar J., Losi L., Lee J.Q., Wang S.T., Clarke P.A., Bell S., Quirke P., Bubb V.J., Piris J., Cruickshank N.R., Morton D., Fox J.C., Al-Mulla F., Lees N., Hall C.N., Snary D., Wilkinson K., Dillon D., Costa J., Pricolo V.E., Finkelstein S.D., Thebo J.S., Senagore A.J., Halter S.A., Wadler S., Malik S., Krtolica K., Urosevic N. Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Brit. J. Cancer 2001, 85:692-696.
14. Lievre A., Bachet J.B., Le Corre D., Boige V., Landi B., Emile J.F., Cote J.F., Tomasic G., Penna C., Ducreux M., Rougier P., Penault-Llorca F., Laurent-Puig P. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 2006, 66:3992-3995.
15. Di Fiore F., Blanchard F., Charbonnier F., Le Pessot F., Lamy A., Galais M.P., Bastit L., Killian A., Sesboue R., Tuech J.J., Queuniet A.M., Paillot B., Sabourin J.C., Michot F., Michel P., Frebourg T. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Brit. J. Cancer 2007, 96:1166-1169.
16. Douillard J.Y., Siena S., Cassidy J., Tabernero J., Burkes R., Barugel M., Humblet Y., Bodoky G., Cunningham D., Jassem J., Rivera F., Kocakova I., Ruff P., Blasinska-Morawiec M., Smakal M., Canon J.L., Rother M., Oliner K.S., Wolf M., Gansert J. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J. Clin. Oncol. 2010, 28:4697-4705.
17. Peeters M., Price T.J., Cervantes A., Sobrero A.F., Ducreux M., Hotko Y., Andre T., Chan E., Lordick F., Punt C.J., Strickland A.H., Wilson G., Ciuleanu T.E., Roman L., Van Cutsem E., Tzekova V., Collins S., Oliner K.S., Rong A., Gansert J. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J. Clin. Oncol. 2010, 28:4706-4713.
18. Van Cutsem E., Kohne C.H., Lang I., Folprecht G., Nowacki M.P., Cascinu S., Shchepotin I., Maurel J., Cunningham D., Tejpar S., Schlichting M., Zubel A., Celik I., Rougier P., Ciardiello F., Cetuximab Plus Irinotecan, Fluorouracil Leucovorin As first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J. Clin. Oncol. 2011, 29:2011-2019.
19. Bokemeyer C., Bondarenko I., Hartmann J.T., de Braud F., Schuch G., Zubel A., Celik I., Schlichting M., Koralewski P. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann. Oncol. 2011, 22:1535-1546.
20. Shirasawa S., Furuse M., Yokoyama N., Sasazuki T. Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. Science 1993, 260:85-88.
21. Pollock C.B., Shirasawa S., Sasazuki T., Kolch W., Dhillon A.S. Oncogenic K-RAS is required to maintain changes in cytoskeletal organization, adhesion, and motility in colon cancer cells. Cancer Res. 2005, 65:1244-1250.
22. Haigis K.M., Kendall K.R., Wang Y., Cheung A., Haigis M.C., Glickman J.N., Niwa-Kawakita M., Sweet-Cordero A., Sebolt-Leopold J., Shannon K.M., Settleman J., Giovannini M., Jacks T. Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. Nat. Genet. 2008, 40:600-608.
23. Rosen K., Rak J., Leung T., Dean N.M., Kerbel R.S., Filmus J. Activated Ras prevents downregulation of Bcl-X(L) triggered by detachment from the extracellular matrix. A mechanism of Ras-induced resistance to anoikis in intestinal epithelial cells. J. Cell Biol. 2000, 149:447-456.
24. Rak J., Mitsuhashi Y., Bayko L., Filmus J., Shirasawa S., Sasazuki T., Kerbel R.S. Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res. 1995, 55:4575-4580.
25. Okada F., Rak J.W., Croix B.S., Lieubeau B., Kaya M., Roncari L., Shirasawa S., Sasazuki T., Kerbel R.S. Impact of oncogenes in tumor angiogenesis: mutant K-ras up-regulation of vascular endothelial growth factor/vascular permeability factor is necessary, but not sufficient for tumorigenicity of human colorectal carcinoma cells. Proc. Natl Acad. Sci. U. S. A. 1998, 95:3609-3614.
26. Ries S., Biederer C., Woods D., Shifman O., Shirasawa S., Sasazuki T., McMahon M., Oren M., McCormick F. Opposing effects of Ras on p53: transcriptional activation of mdm2 and induction of p19ARF. Cell 2000, 103:321-330.
27. Bernhard E.J., Stanbridge E.J., Gupta S., Gupta A.K., Soto D., Bakanauskas V.J., Cerniglia G.J., Muschel R.J., McKenna W.G. Direct evidence for the contribution of activated N-ras and K-ras oncogenes to increased intrinsic radiation resistance in human tumor cell lines. Cancer Res. 2000, 60:6597-6600.
28. Bengala C., Bettelli S., Bertolini F., Salvi S., Chiara S., Sonaglio C., Losi L., Bigiani N., Sartori G., Dealis C., Malavasi N., D'Amico R., Luppi G., Gatteschi B., Maiorana A., Conte P.F. Epidermal growth factor receptor gene copy number, K-ras mutation and pathological response to preoperative cetuximab, 5-FU and radiation therapy in locally advanced rectal cancer. Ann. Oncol. 2009, 20:469-474.
29. Zauber N.P., Marotta S.P., Berman E., Grann A., Rao M., Komati N., Ribiero K., Bishop D.T. Molecular genetic changes associated with colorectal carcinogenesis are not prognostic for tumor regression following preoperative chemoradiation of rectal carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 2009, 74:472-476.
30. Yun J., Rago C., Cheong I., Pagliarini R., Angenendt P., Rajagopalan H., Schmidt K., Willson J.K., Markowitz S., Zhou S., Diaz L.A., Velculescu V.E., Lengauer C., Kinzler K.W., Vogelstein B., Papadopoulos N. Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. Science 2009, 325:1555-1559.
31. Gatenby R.A., Gillies R.J. Why do cancers have high aerobic glycolysis?. Nat. Rev. Cancer 2004, 4:891-899.
32. de Bruijn M.T., Raats D.A., Hoogwater F.J., van Houdt W.J., Cameron K., Medema J.P., Borel Rinkes I.H., Kranenburg O. Oncogenic KRAS sensitises colorectal tumour cells to chemotherapy by p53-dependent induction of Noxa. Brit. J. Cancer 2010, 102:1254-1264.
33. Klampfer L., Swaby L.A., Huang J., Sasazuki T., Shirasawa S., Augenlicht L. Oncogenic Ras increases sensitivity of colon cancer cells to 5-FU-induced apoptosis. Oncogene 2005, 24:3932-3941.
34. Klampfer L., Huang J., Sasazuki T., Shirasawa S., Augenlicht L. Oncogenic Ras promotes butyrate-induced apoptosis through inhibition of gelsolin expression. J. Biol. Chem. 2004, 279:36680-36688.
35. Keller J.W., Haigis K.M., Franklin J.L., Whitehead R.H., Jacks T., Coffey R.J. Oncogenic K-RAS subverts the antiapoptotic role of N-RAS and alters modulation of the N-RAS:gelsolin complex. Oncogene 2007, 26:3051-3059.
36. Luo J., Emanuele M.J., Li D., Creighton C.J., Schlabach M.R., Westbrook T.F., Wong K.K., Elledge S.J. A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 2009, 137:835-848.
37. Johnson L., Greenbaum D., Cichowski K., Mercer K., Murphy E., Schmitt E., Bronson R.T., Umanoff H., Edelmann W., Kucherlapati R., Jacks T. K-ras is an essential gene in the mouse with partial functional overlap with N-ras. Genes Dev. 1997, 11:2468-2481.
38. Janssen K.P., el-Marjou F., Pinto D., Sastre X., Rouillard D., Fouquet C., Soussi T., Louvard D., Robine S. Targeted expression of oncogenic K-ras in intestinal epithelium causes spontaneous tumorigenesis in mice. Gastroenterology 2002, 123:492-504.
39. Johnson L., Mercer K., Greenbaum D., Bronson R.T., Crowley D., Tuveson D.A., Jacks T. Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature 2001, 410:1111-1116.
40. Guerra C., Mijimolle N., Dhawahir A., Dubus P., Barradas M., Serrano M., Campuzano V., Barbacid M. Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context. Cancer Cell 2003, 4:111-120.
41. Ireland H., Kemp R., Houghton C., Howard L., Clarke A.R., Sansom O.J., Winton D.J. Inducible Cre-mediated control of gene expression in the murine gastrointestinal tract: effect of loss of beta-catenin. Gastroenterology 2004, 126:1236-1246.
42. Sansom O.J., Meniel V., Wilkins J.A., Cole A.M., Oien K.A., Marsh V., Jamieson T.J., Guerra C., Ashton G.H., Barbacid M., Clarke A.R. Loss of Apc allows phenotypic manifestation of the transforming properties of an endogenous K-ras oncogene in vivo. Proc. Natl Acad. Sci. U. S. A. 2006, 103:14122-14127.
43. Tuveson D.A., Shaw A.T., Willis N.A., Silver D.P., Jackson E.L., Chang S., Mercer K.L., Grochow R., Hock H., Crowley D., Hingorani S.R., Zaks T., King C., Jacobetz M.A., Wang L., Bronson R.T., Orkin S.H., DePinho R.A., Jacks T. Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell 2004, 5:375-387.
44. Wong M.H., Saam J.R., Stappenbeck T.S., Rexer C.H., Gordon J.I. Genetic mosaic analysis based on Cre recombinase and navigated laser capture microdissection. Proc. Natl Acad. Sci. U. S. A. 2000, 97:12601-12606.
45. el Marjou F., Janssen K.P., Chang B.H., Li M., Hindie V., Chan L., Louvard D., Chambon P., Metzger D., Robine S. Tissue-specific and inducible Cre-mediated recombination in the gut epithelium. Genesis 2004, 39:186-193.
46. Calcagno S.R., Li S., Colon M., Kreinest P.A., Thompson E.A., Fields A.P., Murray N.R. Oncogenic K-ras promotes early carcinogenesis in the mouse proximal colon International journal of cancer. Int. J. Cancer 2008, 122:2462-2470.
47. Bennecke M., Kriegl L., Bajbouj M., Retzlaff K., Robine S., Jung A., Arkan M.C., Kirchner T., Greten F.R. Ink4a/Arf and oncogene-induced senescence prevent tumor progression during alternative colorectal tumorigenesis. Cancer Cell 2010, 18:135-146.
48. Trobridge P., Knoblaugh S., Washington M.K., Munoz N.M., Tsuchiya K.D., Rojas A., Song X., Ulrich C.M., Sasazuki T., Shirasawa S., Grady W.M. TGF-beta receptor inactivation and mutant Kras induce intestinal neoplasms in mice via a beta-catenin-independent pathway. Gastroenterology 2009, 136:1680-1688. e1687.
49. Lyda M.H., Noffsinger A., Belli J., Fenoglio-Preiser C.M. Microsatellite instability and K-ras mutations in patients with ulcerative colitis. Hum. Pathol. 2000, 31:665-671.
50. Wong N.A., Harrison D.J. Colorectal neoplasia in ulcerative colitis-recent advances. Histopathology 2001, 39:221-234.
51. Fearon E.R., Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990, 61:759-767.
52. Janssen K.P., Alberici P., Fsihi H., Gaspar C., Breukel C., Franken P., Rosty C., Abal M., El Marjou F., Smits R., Louvard D., Fodde R., Robine S. APC and oncogenic KRAS are synergistic in enhancing Wnt signaling in intestinal tumor formation and progression. Gastroenterology 2006, 131:1096-1109.
53. Colnot S., Niwa-Kawakita M., Hamard G., Godard C., Le Plenier S., Houbron C., Romagnolo B., Berrebi D., Giovannini M., Perret C. Colorectal cancers in a new mouse model of familial adenomatous polyposis: influence of genetic and environmental modifiers. Lab. Invest. 2004, 84:1619-1630.
54. Hung K.E., Maricevich M.A., Richard L.G., Chen W.Y., Richardson M.P., Kunin A., Bronson R.T., Mahmood U., Kucherlapati R. Development of a mouse model for sporadic and metastatic colon tumors and its use in assessing drug treatment. Proc. Natl Acad. Sci. U. S. A. 2010, 107:1565-1570.
55. Li J., Mizukami Y., Zhang X., Jo W.S., Chung D.C. Oncogenic K-ras stimulates Wnt signaling in colon cancer through inhibition of GSK-3beta. Gastroenterology 2005, 128:1907-1918.
56. Rinehart J., Adjei A.A., Lorusso P.M., Waterhouse D., Hecht J.R., Natale R.B., Hamid O., Varterasian M., Asbury P., Kaldjian E.P., Gulyas S., Mitchell D.Y., Herrera R., Sebolt-Leopold J.S., Meyer M.B. Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J. Clin. Oncol. 2004, 22:4456-4462.
57. Serrano M., Lin A.W., McCurrach M.E., Beach D., Lowe S.W. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 1997, 88:593-602.
58. Biswas S., Trobridge P., Romero-Gallo J., Billheimer D., Myeroff L.L., Willson J.K., Markowitz S.D., Grady W.M. Mutational inactivation of TGFBR2 in microsatellite unstable colon cancer arises from the cooperation of genomic instability and the clonal outgrowth of transforming growth factor beta resistant cells. Gene Chromosome Cancer 2008, 47:95-106.
59. Duval A., Hamelin R. Mutations at coding repeat sequences in mismatch repair-deficient human cancers: toward a new concept of target genes for instability. Cancer Res 2002, 62:2447-2454.
60. Jakowlew S.B. Transforming growth factor-beta in cancer and metastasis. Cancer Metastasis Rev. 2006, 25:435-457.
61. Baba I., Shirasawa S., Iwamoto R., Okumura K., Tsunoda T., Nishioka M., Fukuyama K., Yamamoto K., Mekada E., Sasazuki T. Involvement of deregulated epiregulin expression in tumorigenesis in vivo through activated Ki-Ras signaling pathway in human colon cancer cells. Cancer Res. 2000, 60:6886-6889.